Vanderbilt Ingram Cancer Center

For more VICC news, visit their website »

x-ray of stomach
October 12, 2023

Symposium for patients, caregivers and family members offers important information on stomach cancer, Nov. 4

A Vanderbilt symposium on Nov. 4 offers detailed information for patients, caregivers and family members about stomach cancer.

By Tom Wilemon
Blane Hollingsworth, PhD, was the first patient at VUMC to undergo a liver transplant under the protocol for cholangiocarcinoma.
October 10, 2023

Multidisciplinary care crucial in guiding Vanderbilt employee’s bile duct cancer journey

Blane Hollingsworth became the first patient at Vanderbilt to undergo a liver transplant under the protocol for cholangiocarcinoma, or bile duct cancer.

By Matt Batcheldor
x-ray of stomach
October 5, 2023

Study validates pyrvinium as treatment to prevent stomach cancer

A Vanderbilt study found that a drug that has been used for decades for intestinal pinworms, can be repurposed as a preventative treatment for stomach cancer.

By Tom Wilemon
The study team included, from left, Paula Gonzalez-Ericsson, MD, Xiaopeng Sun, Justin Balko, PharmD, PhD, and Brandie Taylor, MS. (photo by Donn Jones)
October 4, 2023

Vulnerability found in immunotherapy-resistant triple-negative breast cancer

Vanderbilt researchers have discovered a druggable target on natural killer cells that could potentially trigger a therapeutic response in patients with immunotherapy-resistant, triple-negative breast cancer.

By Tom Wilemon
September 12, 2023

Study finds new genetic susceptibilities for colon cancer

Vanderbilt researchers at have found new genes that put people at higher risk for colon cancer and rectal cancer. 

By Tom Wilemon
Houra Merrikh and Juan Carvajal-Garcia, PhD, are studying how to prevent cancer therapy resistance. (photo by Erin O. Smith)
September 1, 2023

Foundation funds research to block drug resistance in cancer treatment

The Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation has funded an ambitious initiative to overcome one of the most perplexing and frustrating mysteries of cancer treatment — how to prevent drug resistance.

By Tom Wilemon
August 17, 2023

Vanderbilt-Ingram Cancer Center hosts Korean American Symposium

Vanderbilt-Ingram Cancer Center recently hosted the first of a planned series of events to highlight the diversity of oncology researchers and to nurture networking opportunities for them.
By Tom Wilemon
August 10, 2023

New leaders named to Vanderbilt-Ingram research programs

Seven new leaders have been appointed to guide Vanderbilt-Ingram Cancer Center’s research programs.
By Tom Wilemon
August 8, 2023

Chronic complications from immunotherapies more prevalent and persistent than previously shown among melanoma survivors

A Vanderbilt study has found that chronic immunotherapy-related complications are more prevalent and persistent than previously shown among melanoma survivors.
By Tom Wilemon
July 26, 2023

International workgroup of geneticists issues CHEK2 guidelines

International workgroup issues additional guidance on how to manage patients who carry inherited CHEK2 gene mutations that put them at a higher risk for cancer.
By Tom Wilemon
July 20, 2023

Stem cell recipient meets donor who saved her life 10 years ago

Each passing day is precious for Deneen Eastridge, but a decade is a priceless gift. The Dallas resident came to Nashville recently to meet Trina Hughes, the stem cell donor who gave her the gift of life 10 years ago.
By Tom Wilemon
July 19, 2023

Holowatyj receives National Cancer Institute MERIT Award

Vanderbilt's Andreana Holowatyj, PhD, MSCI, has received the National Cancer Institute’s Method to Extend Research in Time Award to support her ongoing investigation into how early-onset colorectal cancer and its treatments impact reproductive health.
By Tom Wilemon
June 29, 2023

Study identifies key regulator of melanoma development

Vanderbilt investigators have revealed the mechanisms by which the chemokine receptor CXCR2, is associated with melanoma tumor formation and growth — a discovery that supports the continued development of drugs that inhibit the receptor’s activity.
By Tom Wilemon
1 2 3 4 … 58